- Spain CIMA (Spanish): search for “piracetam” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- End-stage kidney disease
- Cerebral hemorrhage
- Huntington chorea
- Hypersensitivity to piracetam or other pyrrolidone derivatives
Dosing: Adult
- Cortical myoclonus: Start 7.2 g/day, increase by 4.8 g/day every 3 to 4 days to a maximum of 24 g/day in 2 or 3 doses; taper by 1.2 g every 2 days when stopping
- Psycho-organic syndromes or vertigo: 2.4 to 4.8 g/day in 2 or 3 doses
Dosing: Altered kidney function
About 90% of piracetam is excreted unchanged in urine, so the dose falls in steps with creatinine clearance (CrCl): two-thirds at 50–79, one-third at 30–49 and one-sixth (once daily) below 30 mL/min. It is contraindicated in end-stage kidney disease, and hemodialysis removes 50% to 60%. It also inhibits platelet aggregation. It has no US FDA label.
Kidney function measure: European core safety profile uses creatinine clearance (CrCl, mL/min; Cockcroft–Gault, ×0.85 for women).
Show full dosing details
- CrCl ≥60 mL/min
- CrCl >80: usual dose in 2 to 4 divided doses (e.g., 2.4 to 4.8 g/day; up to 24 g/day for cortical myoclonus). CrCl 60–79: two-thirds of the usual dose in 2 or 3 divided doses (CSP).
- CrCl 30–59 mL/min
- CrCl 50–59: two-thirds of the usual daily dose in 2 or 3 divided doses. CrCl 30–49: one-third of the usual daily dose in 2 divided doses (CSP).
- CrCl 15–29 mL/min
- CrCl <30: one-sixth of the usual daily dose as a single daily dose (CSP).
- CrCl <15 mL/min (not on dialysis)
- CrCl <30: one-sixth of the usual daily dose once daily. End-stage kidney disease: contraindicated (CSP). Equating CrCl <15 with end-stage disease is our judgment; we keep it red because piracetam is renally cleared, of marginal benefit and affects platelets in a population prone to uremic bleeding.
- Hemodialysis (intermittent)
- Contraindicated in end-stage kidney disease (CSP). Hemodialysis removes 50% to 60% (dialyzer extraction), useful in overdose.
- Peritoneal dialysis
- Contraindicated in end-stage kidney disease (CSP).
- CRRT
- Not appropriate; contraindicated in end-stage kidney disease and no data in acute kidney injury.
- Dialyzable? Yes: hemodialysis extraction efficiency 50% to 60% (CSP 4.9).
- Monitoring Creatinine clearance regularly in older adults and long-term use. Bleeding risk (platelet inhibition): caution with anticoagulants, antiplatelets, ulcer, recent surgery or hemorrhagic stroke. Do not stop abruptly in myoclonus (CSP 4.4).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Normal kidney function: usual pediatric doses (CSP).
- eGFR 30–59
- No pediatric-specific table; the adult CrCl-based fractions are the only guide (renally cleared drug). Specialist input.
- eGFR 15–29
- No pediatric-specific table; the adult CrCl-based fractions are the only guide (renally cleared drug). Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric-specific table; the adult CrCl-based fractions are the only guide (renally cleared drug). Specialist input.
- Hemodialysis (intermittent)
- Contraindicated in end-stage kidney disease.
- Peritoneal dialysis
- Contraindicated in end-stage kidney disease.
- CRRT
- Contraindicated in end-stage kidney disease.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: CBG-MEB (Netherlands) product information. This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Dyslexia from 8 years; sickle cell crises from 3 years (limited data 1 to 3 years) (CSP).
- Usual dose
- Dyslexia (8 years and older): about 3.2 g/day in 2 doses. Sickle cell: 160 mg/kg/day orally (prophylaxis); 300 mg/kg/day intravenously (crisis) (CSP).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 1.2 g, 800 mg
- Capsule: 400 mg
- Solution for injection: 200 mg/mL
- ) solution for injection: 200 mg/mL (1 g/5 mL
- Tablet: 1.2 g, 800 mg
- ) solution for infusion: 200 mg/mL (1 g/5 mL
Registered products in the Philippines
30 products registered with the Food and Drug Administration (FDA) Philippines list Piracetam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products30
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BoricetamPiracetam | 200 mg/mL (1 g/5 mL) Solution for Injection (I.M./I.V.)Type I Amber Glass Ampoule in 5 mL (net content) (Box of 10’s) | RxVAT-exempt | Brawn Laboratories LimitedIndia | L’Keeran EnterprisesImporter: Ambica International Corporation | DRP-8045 | Dec 5, 2028 | |
BoricetamPiracetam | 400 mg CapsuleAlu/PVC Blister Pack x 10’s (Box of 100 capsules) | RxVAT-exempt | Brawn Laboratories Ltd.India | Ambica International Corporation | DRP-6662 | Apr 27, 2037 | |
CognizetPiracetam | 200mg/ml Solution for Injection (IV/IM/SC)Clear glass ampoule with band x 5mL (Box of 1's) | RxVAT-exempt | Sanjar Pharma LLPIndia | Aglobal Care, Inc. | DRP-15550 | Aug 5, 2029 | |
EmbolPiracetam | 200 mg/mL Solution for Injection (I.M./I.V.)Ampoule x 5 mL (Box of 10's) | RxVAT-exempt | Yung Shin Pharm. Ind. Co., Ltd. - Taichung Youth FactoryTaiwan | Philgen Pharmaceuticals Inc.Importer: Yung Shin (Philippines), Inc. | DR-XY12988 | Dec 6, 2030 | |
EmbolPiracetam | 200 mg/mL Solution For Injection (IM/IV)USP Type I clear glass ampoule x 5 mL (Box of 10's) | RxVAT-exempt | Y.S.P. Industries (M) SDN. BHD.Malaysia | Yung Shin (Philippines), Inc. | DR-XY48306 | Aug 22, 2027 | |
EucetPiracetam | 1.2 g Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc. | DRP-2913 | May 15, 2031 | |
IracetPiracetam | 400 mg CapsuleBlister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Tgp Pharma Inc.Trader: Foramen Products Corporation | DR-XY31588 | Apr 7, 2031 | |
IracetPiracetam | 800 mg Film-Coated TabletBlister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Foramen Products Corporation | DR-XY31790 | May 25, 2031 | |
KnowfulPiracetam | 800 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Y.S.P. Industries (M) Sdn. BhdMalaysia | Yung Shin (Philippines), Inc. | DR-XY49133 | Aug 14, 2029 | |
NeuracetPiracetam | 200 mg/mL Solution for Injection (IM/IV)Type I Clear Colorless Ampoule x 20 mL (Box of 5's) | RxVAT-exempt | Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China | Endure Medical, Inc. | DR-XY43515 | Jul 10, 2029 | |
NeurocetamPiracetam | 1.2 g TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY42110 | Jun 13, 2028 | |
NeurocetamPiracetam | 200 mg/mL Solution for Injection ( iM/IV)USP Type I Clear Glass Ampoule x 15 mL (Box of 4's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY35480 | Nov 7, 2031 | |
NeurocetamPiracetam | 800 mg tabletAlu/ Orange PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc.Importer: Brown & burk Philippines Inc. | DR-XY34886 | Sep 3, 2031 | |
NeurotamPiracetam | 800 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DRP-16441 | Sep 20, 2030 | |
NeutrotopPiracetam | 1.2 g Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Randril International Co., Inc. | DRP-4345 | Apr 12, 2027 | |
NootropilPiracetam | 800 mg Film-Coated Tablet | RxVAT-exempt | UCB Pharma S.A. | Importer: GlaxoSmithKline Philippines Inc. | DR-X5323 | Dec 28, 2026 | |
NootrotamPiracetam | 200 mg/mL (1 g/5 mL) Solution for Infusion (I.M./I.V.)5 mL Type I amber glass ampoule (Box of 12's) | RxVAT-exempt | Osel Ilaç San. Ve Tic A.Ş.Turkey | Access Point International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-11799 | Apr 29, 2027 | |
Normabrain-800Piracetam | 800 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 50's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines Inc. | DRP-2764 | Nov 17, 2031 | |
NurocerPiracetam | 1.2 g Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-9910 | Nov 22, 2029 | |
NurocerPiracetam | 400 mg CapsuleBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-9990 | Apr 21, 2030 | |
NurocerPiracetam | 800 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-9911 | Nov 19, 2029 | |
Nurocer IVPiracetam | 200 mg/mL (1 g/5 mL) Solution for Injection (I.M./I.V.)Type I Amber Glass Ampoule in 5 mL (net content) (Box of 10’s) | RxVAT-exempt | Brawn Laboratories LimitedIndia | Innogen Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-8045-01 | Dec 5, 2028 | |
PerixlPiracetam | 800 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3990-01 | Mar 22, 2032 | |
ProtamPiracetam | 1.2 g Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Aldril Phamraceuticals, Inc.Trader: Randril Internation Co., Inc. | DRP-4345-01 | Apr 12, 2027 | |
Retento-400Piracetam | 400 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3061 | Jun 16, 2032 | |
Retento-800Piracetam | 800 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box 30’s and 60’s) | RxVAT-exempt | Xl Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3990 | Mar 22, 2032 | |
Saphcetam-400Piracetam | 400 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ollen Pharma Trading, Inc. | DRP-12882 | Oct 24, 2027 | |
Saphcetam-800Piracetam | 800mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ollen Pharma Trading, Inc. | DRP-12803 | Oct 7, 2027 | |
Saphneuropi-GE800Piracetam | 800 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-18949 | Oct 6, 2031 | |
ZystamPiracetam | 800 mg Film-Coated TabletAlu/PVDC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | The Schazoo Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Zuneca Inc. | DR-XY36957 | Nov 11, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Anticoagulants, antiplatelets (including low-dose aspirin) | Adjust or monitor | Piracetam lowers platelet aggregation, fibrinogen and von Willebrand factor. | Use with caution; watch for bleeding. |
| Thyroid hormones (T3 plus T4) | Minor | Confusion, irritability, sleep disorder reported. | Monitor. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Nervousness
- Hyperkinesia
- Weight gain
Serious
- Bleeding (hemorrhagic disorder)
- Anaphylactoid reactions, angioedema
- Aggravated epilepsy, hallucinations
Monitoring parameters
- Creatinine clearance regularly in older adults and long-term use. Bleeding risk (platelet inhibition): caution with anticoagulants, antiplatelets, ulcer, recent surgery or hemorrhagic stroke. Do not stop abruptly in myoclonus (CSP 4.4). Kidney
- Creatinine clearance in older adults and long-term use
- Bleeding signs
Pharmacokinetics
Key PK parameters
| Renal excretion kidney | About 90% unchanged in urine |
|---|---|
| Dialyzability kidney | Yes (hemodialysis extraction 50% to 60%) |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Medicines Evaluation Board (CBG-MEB), Netherlands. Piracetam proposed core safety profile (sections 4.2–4.9) [CBG-MEB (Netherlands) product information; no US FDA label]. https://db.cbg-meb.nl/veegactie/csp/piracetam-6-2010.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board, Netherlands). (n.d.; c. 2010). Piracetam: Proposed core safety profile, sections 4.2–4.9 [Harmonization document]. Retrieved November 17, 2026. https://db.cbg-meb.nl/veegactie/csp/piracetam-6-2010.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .